At the news
? MIXEDIMPACT 6/10 PRESS-RELEASE filed Apr 3, 2026 at 13:30 ET
Denali Therapeutics announced that Takeda has terminated their collaboration on DNL593, an investigational therapy for frontotemporal dementia caused by granulin mutations (FTD-GRN), for strategic reasons unrelated to safety or efficacy. Denali will now advance DNL593 independently, with Phase 1/2 trial results expected by the end of 2026. The company retains full rights to the program and its proprietary TransportVehicle™ platform, which enables blood-brain barrier penetration.
- Takeda terminated its collaboration with Denali on DNL593 for strategic reasons, not due to safety or efficacy concerns.
- Denali regains full control of DNL593 and its intellectual property, allowing independent development.
- Phase 1/2 trial in FTD-GRN patients is fully enrolled (n=40), with data expected by end of 2026.
- Interim data in healthy volunteers showed dose-dependent increases in cerebrospinal fluid progranulin, indicating brain delivery.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access